Deva Holding AS 2024 AR2
The report highlights DEVA Holding's performance in 2024, marking its 66th anniversary. The company maintained its strong market position in Turkey, ranking 3rd in unit sales with a 5.3% market share and expanding its international presence to 1,404 product registrations across 82 countries. DEVA Holding was recognized as the pharmaceutical company with the highest R&D expenditure in Turkey, employing 504 expert researchers at its DEVARGE center. Financially, the company recorded net sales revenue of TRY 15,458,482,050 and a net profit of TRY 69,419,646. On sustainability, the company established a Sustainability Subcommittee and continues to align its operations with ISO 14001 standards across all manufacturing facilities.
Company: Deva Holding AS
Sector: Health Care
Country: Turkiye
Year: 2024
Type: AR2
Pages: 44
Deva Holding AS
Annual Report
The report highlights DEVA Holding's performance in 2024, marking its 66th anniversary. The company maintained its strong market position in Turkey, ranking 3rd in unit sales with a 5.3% market share and expanding its international presence to 1,404 product registrations across 82 countries. DEVA Holding was recognized as the pharmaceutical company with the highest R&D expenditure in Turkey, employing 504 expert researchers at its DEVARGE center. Financially, the company recorded net sales revenue of TRY 15,458,482,050 and a net profit of TRY 69,419,646. On sustainability, the company established a Sustainability Subcommittee and continues to align its operations with ISO 14001 standards across all manufacturing facilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees